ClinicalTrials.gov
public full text
Public Domain
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
This study is expected to recruit 30 patients with unresectable HCC who will be treated with Donafenib combined with PD-1 + TACE. During the study period, the tumor efficacy and resectability will be evaluated by imaging examination every 6 weeks. Patients with successful transformation can choose hepatectomy or observation. During the study, safety evaluation and effectiveness evaluation will be carried out.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion#828306
- Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation#860249
- Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT#1140890
- Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors#993232
- SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma#1058756
Record · ID 863433
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive